Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Eikon Therapeutics’ $381 million upsized IPO marks the busiest week for biotech public offerings since early 2025, signaling that the “class of 2021” unicorns may
The Department of Health and Human Services launched a $100 million competition for broad-spectrum antivirals yesterday, signaling a decisive policy shift away from mRNA vaccines
Daily Update: FDA PreCheck Launch, Sanofi Venglustat Results The FDA’s new PreCheck pilot program opens for applications as the agency moves to reshore pharmaceutical manufacturing.
Weekly Update: Telehealth Reversion, Obesity Platform Race Today marks Day One of post-pandemic Medicare telehealth. With Congress failing to extend flexibilities through the weekend, health
GRAIL Galleri PMA, Formation Bio $500M, Summit BLA A structural transition is underway: GRAIL’s PMA submission for Galleri marks a watershed moment for liquid biopsy
Cellares $257M, Regenxbio Hold, Skyhawk Huntington’s High-conviction capital is flooding cell therapy infrastructure as Cellares secures a $257M Series D to industrialize manufacturing. Meanwhile, a
UnitedHealth Crashes 20%, Intellia Hold Lifted | Jan 2026 A structural repricing of the managed care sector (-20% UNH) following disappointing Medicare Advantage rates and
Tuesday Brief: Capital Gets Conditional Monday’s session reinforced a “Capital Gets Conditional” regime: multi-year clinical durability (Sarepta) and clear regulatory differentiation (Guardant) are being rewarded,
Last week confirmed a shift from asset acquisition toward structured optionality, with milestone-heavy dealmaking in oncology and immunology accelerating alongside FDA clearances that reinforce momentum
Big Pharma business development and late-stage venture capital converged today around differentiated platforms. Bristol Myers Squibb committed $850 million to tumor-activated T-cell engagers through a
